![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Antisense technology continues to progress, with a number of anti-sense drugs in broad clinical trials, and antisense drugs based on second and third generation chemistry now in detailed animal studies. ISIS 2922, administered intravitreally to treat cytomegalovirus-associated retinitis, is the most advanced and has entered Phase III trials. GEM 91, an anti-AIDS antisense drug, and ISIS 2302, an anti-ICAM drug, are in Phase II trials. Three antisense drugs with potential as anticancer agents, ISIS 3521, ISIS 5132 and ISIS 6139, are in Phase I trials.